Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia

2012 ◽  
Vol 19 (1) ◽  
pp. 119-122 ◽  
Author(s):  
Gábor Rubovszky ◽  
Tünde Nagy ◽  
Mária Gődény ◽  
András Szász ◽  
István Láng
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Successful Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Solitary Bone Metastasis

scholarly journals Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts

2021 ◽  
Vol 12 (7) ◽  
Author(s):  
Jianjiao Ni ◽  
Xiaofei Zhang ◽  
Juan Li ◽  
Zhiqin Zheng ◽  
Junhua Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Osteoclast Differentiation ◽  
Small Cell ◽  
Signalling Pathway ◽  
Small Cell Lung

AbstractBone is a frequent metastatic site of non-small cell lung cancer (NSCLC), and bone metastasis (BoM) presents significant challenges for patient survival and quality of life. Osteolytic BoM is characterised by aberrant differentiation and malfunction of osteoclasts through modulation of the TGF-β/pTHrP/RANKL signalling pathway, but its upstream regulatory mechanism is unclear. In this study, we found that lncRNA-SOX2OT was highly accumulated in exosomes derived from the peripheral blood of NSCLC patients with BoM and that patients with higher expression of exosomal lncRNA-SOX2OT had significantly shorter overall survival. Additionally, exosomal lncRNA-SOX2OT derived from NSCLC cells promoted cell invasion and migration in vitro, as well as BoM in vivo. Mechanistically, we discovered that NSCLC cell-derived exosomal lncRNA-SOX2OT modulated osteoclast differentiation and stimulated BoM by targeting the miRNA-194-5p/RAC1 signalling axis and TGF-β/pTHrP/RANKL signalling pathway in osteoclasts. In conclusion, exosomal lncRNA-SOX2OT plays a crucial role in promoting BoM and may serve as a promising prognostic biomarker and treatment target in metastatic NSCLC.

Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer

2011 ◽  
Vol 39 (3) ◽  
pp. 3029-3035 ◽  
Author(s):  
Na Li ◽  
Jian-ping Zhang ◽  
Shan Guo ◽  
Jie Min ◽  
Li–li Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Down Regulation ◽  
Β3 Integrin

scholarly journals Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

2015 ◽  
Vol 10 (1) ◽  
pp. 386-388 ◽  
Author(s):  
HIROKO WATANABE ◽  
TOMOHIRO TAMURA ◽  
KATSUNORI KAGOHASHI ◽  
NORIO TAKAYASHIKI ◽  
KOICHI KURISHIMA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Successful Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Reduced Dose ◽  
Egfr Mutated

Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer

Lung Cancer ◽  
2015 ◽  
Vol 88 (1) ◽  
pp. 112-113 ◽  
Author(s):  
Tomonobu Koizumi ◽  
Toshirou Fukushima ◽  
Toshiharu Tatai ◽  
Takashi Kobayashi ◽  
Nodoka Sekiguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Successful Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive
Sign in / Sign up

Export Citation Format

Share Document